XFOR X4 PHARMACEUTICALS
Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about X4 PHARMACEUTICALS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 3 reports on XFOR from 3 analyst firms in the last 90 days (8 firms in the past year).
Comparing each firm's latest target with its previous one: 2 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Brookline Capital Markets | Leah R Cann | Buy | 6 Aug 2026 | 13.00 USD |
| Guggenheim | Michael Schmidt | Buy | 9 Sep 2026 | 12.00 USD |
| H.C. Wainwright | Unnamed analyst | Buy | 10 Nov 2025 | 5.00 USD |
| Leerink Partners | Thomas Smith | Buy | 2 Jun 2026 | 12.00 USD |
| Stifel | James Condulis | Buy | 5 Dec 2025 | 10.00 USD |
| Weiss Ratings | Unnamed analyst | — | 20 Oct 2026 | — |
| Wells Fargo | Derek C Archila | Buy | 26 Oct 2026 | 11.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:02 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.